Is Bharat Immunologicals & Biologicals Corporation a good quality company?

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Bharat Immunologicals & Biologicals Corporation Ltd is a below average quality company .

Is Bharat Immunologicals & Biologicals Corporation undervalued or overvalued?

The key valuation ratios of Bharat Immunologicals & Biologicals Corporation Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone .

What is Bharat Immunologicals & Biologicals Corporation share price return in the past 10 years?

Bharat Immunologicals & Biologicals Corporation Ltd share price has declined -6.7% annually (CAGR) over the past ten years.

Is Bharat Immunologicals & Biologicals Corporation a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Bharat Immunologicals & Biologicals Corporation Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

What is the P/E ratio of Bharat Immunologicals & Biologicals Corporation?

The latest standalone P/E ratio of Bharat Immunologicals & Biologicals Corporation as of 21-Nov-2024 is 0.00.

What is the P/B ratio of Bharat Immunologicals & Biologicals Corporation?

The latest standalone P/B ratio of Bharat Immunologicals & Biologicals Corporation as of 21-Nov-2024 is 0.00.

What is the 52-week high and low of Bharat Immunologicals & Biologicals Corporation?

The 52-week high of Bharat Immunologicals & Biologicals Corporation is Rs. 43.89 and the 52-week low is Rs. 22.25.

Bharat Immunologicals & Biologicals Corporation Ltd - Stock Valuation and Financial Performance

Name: Bharat Immunologicals & Biologicals Corporation
Brand: Bharat Immunologicals & Biologicals Corporation

BSE: 524663 | NSE: | Pharmaceuticals & Drugs | Small Cap

Place order

Bharat Immunological Share Price

₹23.06 -0.72 -3.03%
as on 21-Nov'24 16:59

10 Year X-Ray of Bharat Immunological:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Standalone Basis ^P Consolidated Basis

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	TTM
ROCE % ⓘ	42.3%	9.1%	-8.5%	31.1%	-17.5%	-10.7%	-21.9%	-73.1%	-8.1%	-25.6%	-
Value Creation Index ⓘ	2.0	-0.4	-1.6	1.2	-2.3	-1.8	-2.6	-6.2	NA	NA	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	203	146	128	124	34.8	83.7	66.8	85.3	78.4	44.6	45
Sales YoY Gr.	-	-27.9%	-12.4%	-3%	-72%	140.4%	-20.1%	27.7%	-8.1%	-43.1%	-
Adj EPS ⓘ	1	0.6	-1.4	1.5	-1	-1.9	-2.4	-4.3	-2.1	-3.8	-3.9
YoY Gr.	-	-45.2%	-352.6%	NA	-166.9%	NA	NA	NA	NA	NA	-
BVPS (₹) ⓘ	9.2	9.6	8.1	9.7	8.7	7.1	4.7	0.6	-1.5	-5.3	0
Adj Net Profit ⓘ	4.5	2.5	-6.2	6.4	-4.3	-8.1	-10.3	-18.4	-9.1	-16.5	-17
Cash Flow from Ops. ⓘ	-11.9	7.8	-9.4	-17	2.5	-32.1	34.1	11.8	-42.1	10.9	-
Debt/CF from Ops. ⓘ	0.1	-1.1	-1	0	0	-1	0.1	2.3	-1.9	6.5	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	-15.5%	5.1%	-12.6%	-43.1%
Adj EPS ⓘ	-215.6%	NA	NA	NA
BVPSⓘ	-194.1%	-190.7%	-204%	NA
Share Price	-6.7%	23.6%	-23.3%	-9%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	TTM
Return on Equity % ⓘ	11	6	-16.3	16.6	-10.8	-23.7	-40.3	-67.4	-13.1	-17.1	144.5
Op. Profit Mgn % ⓘ	5.9	3.2	-3.2	10.3	-22.8	-11.1	-15.6	-24.5	-6.3	-35.6	-9.4
Net Profit Mgn % ⓘ	2.2	1.7	-4.9	5.2	-12.3	-9.7	-15.4	-21.5	-11.6	-37	-37.3
Debt to Equity ⓘ	-0	-0.2	0.3	0	0	1.1	0.2	11.6	-12.2	-3.1	0
Working Cap Days ⓘ	87	130	119	74	159	267	541	285	233	410	0
Cash Conv. Cycle ⓘ	6	38	55	46	125	153	250	53	84	209	0

Recent Performance Summary

Return on Equity has increased versus last 3 years average to 144.50%

Sales growth has been subdued in last 3 years -12.61%

Sales growth is not so good in last 4 quarters at -73.20%

Latest Financials - Bharat Immunologicals & Biologicals Corporation Ltd.

	Standalone	Consolidated
TTM EPS (₹)	-3.9	-
TTM Sales (₹ Cr.)	44.6	-
BVPS (₹.) ⓘ	0	-
Reserves (₹ Cr.) ⓘ	-76	-
P/BV ⓘ	0.00	-
PE ⓘ	0.00	-

From the Market
52 Week Low / High (₹)	22.25 / 43.89
All Time Low / High (₹)	0.25 / 94.50
Market Cap (₹ Cr.)	103
Equity (₹ Cr.)	43.2
Face Value (₹)	10
Industry PE ⓘ	43

Management X-Ray of Bharat Immunological:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Valuation of Bharat Immunological

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

This is a premium feature, Please click here to check our solutions.

Key Ratios of Bharat Immunological

Standalone Basis Consolidated Basis

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23
Sales	203	146	128	124	35	84	67	85	78	45
Operating Expenses ⓘ	191	143	132	111	43	93	77	106	83	61
Manufacturing Costs	17	15	13	10	4	11	9	9	8	5
Material Costs	153	111	106	90	27	71	56	81	60	39
Employee Cost	11	10	10	10	10	10	11	14	14	15
Other Costs ⓘ	9	7	3	2	1	1	1	1	2	2
Operating Profit ⓘ	12	3	-4	13	-8	-9	-10	-21	-5	-16
Operating Profit Margin (%)	5.9%	2.3%	-3.1%	10.3%	-22.8%	-11.1%	-15.6%	-24.4%	-6.3%	-36.0%
Other Income ⓘ	6	1	1	1	1	4	1	2	1	1
Interest ⓘ	6	1	6	4	1	2	5	5	6	7
Depreciation ⓘ	1	1	1	1	0	0	0	0	0	0
Exceptional Items ⓘ	0	0	0	0	0	0	0	0	0	0
Profit Before Tax ⓘ	11	2	-9	9	-8	-7	-14	-24	-10	-22
Tax ⓘ	5	1	-3	3	-4	-2	-4	-6	-1	-6
Profit After Tax	6	2	-6	7	-4	-6	-10	-18	-9	-17
PAT Margin (%)	3.2%	1.1%	-4.8%	5.2%	-12.2%	-6.9%	-15.3%	-21.2%	-11.2%	-37.3%
Adjusted EPS (₹)	1.5	0.4	-1.4	1.5	-1.0	-1.3	-2.4	-4.2	-2.0	-3.9
Dividend Payout Ratio (%)	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

Balance Sheet

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23
Equity and Liabilities
Shareholders Fund	40	41	35	42	37	31	20	34	105	88
Share Capital ⓘ	43	43	43	43	43	43	43	43	43	43
Reserves ⓘ	-3	-2	-8	-1	-6	-13	-23	-9	62	45
Minority Interest	0	0	0	0	0	0	0	0	0	0
Debt	-1	-9	9	0	0	32	3	27	78	70
Long Term Debt	0	0	0	0	0	0	0	0	0	0
Short Term Debt	-1	-9	9	0	0	32	3	27	78	70
Trade Payables	32	31	8	0	0	44	44	15	1	1
Others Liabilities ⓘ	20	17	14	13	8	8	46	8	8	3
Total Liabilities ⓘ	91	80	66	55	45	115	113	84	192	162
Fixed Assets
Gross Block	45	6	45	6	6	6	46	46	158	157
Accumulated Depreciation	38	0	40	1	1	1	41	41	42	41
Net Fixed Assetsⓘ	7	6	5	5	5	5	4	4	116	116
CWIP ⓘ	0	0	0	0	0	0	0	32	0	0
Investmentsⓘ	0	0	0	0	0	0	0	0	0	0
Inventories	30	26	22	0	2	14	52	13	36	1
Trade Receivables	26	14	13	6	16	73	18	0	1	14
Cash Equivalents	23	30	20	39	20	8	12	11	13	9
Others Assetsⓘ	4	4	5	3	3	15	27	24	25	22
Total Assets ⓘ	91	80	66	55	45	115	113	84	192	162

Cash Flow

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23
Cash Flow From Operating Activity ⓘ	-12	8	-9	-17	3	-32	34	12	-42	11
PBT ⓘ	11	2	-9	9	-8	-7	-14	-24	-10	-22
Adjustment ⓘ	9	0	1	5	0	0	4	36	5	6
Changes in Working Capital ⓘ	-32	6	-2	-31	10	-25	44	-0	-38	27
Tax Paid ⓘ	0	0	0	0	0	0	0	0	0	0
Cash Flow From Investing Activity ⓘ	0	0	1	0	1	1	1	1	1	0
Capex	0	0	0	0	0	0	0	0	0	0
Net Investments	0	0	0	0	0	0	0	0	0	0
Others ⓘ	0	1	1	1	1	1	1	1	1	0
Cash Flow From Financing Activityⓘ	-6	-1	-2	-3	-3	31	-34	-12	45	-15
Net Proceeds from Shares ⓘ	0	0	0	0	0	0	0	0	0	0
Net Proceeds from Borrowing ⓘ	0	0	0	0	0	0	0	0	0	0
Interest Paid ⓘ	-6	-1	-2	-3	-1	-2	-5	-5	-6	-7
Dividend Paid ⓘ	0	0	0	0	0	0	0	0	0	0
Others ⓘ	-1	0	0	0	-2	33	-30	-7	51	-8
Net Cash Flow ⓘ	-18	7	-10	-20	1	-1	1	0	3	-3

Finance Ratio

Standalone Basis Consolidated Basis

PARTICULARS	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23
Ratios
ROE (%)	15.68	3.81	-16.25	16.94	-10.76	-17	-39.93	-158.64	0	0
ROCE (%)	42.29	9.07	-8.52	31.11	-17.52	-10.7	-21.87	-73.05	-8.08	-25.63
Asset Turnover Ratio	2.31	1.71	1.75	2.06	0.7	1.04	0.59	0.87	0.57	0.25
PAT to CFO Conversion(x)	-2	4	N/A	-2.43	N/A	N/A	N/A	N/A	N/A	N/A
Working Capital Days
Receivable Days	25	50	38	29	117	194	247	38	3	61
Inventory Days	56	69	69	34	11	35	181	139	116	154
Payable Days	81	104	67	16	5	115	286	131	48	9

Bharat Immunologicals & Biologicals Corporation Ltd Stock News

Bharat Immunologicals & Biologicals Corporation Ltd FAQs

What is the share price of Bharat Immunological?

Company share prices are keep on changing according to the market conditions. The closing price of Bharat Immunological on 21-Nov-2024 16:59 is ₹23.06.

What is the market cap of Bharat Immunological?

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 21-Nov-2024 16:59 the market cap of Bharat Immunological stood at ₹102.7.

What is the P/E ratio of Bharat Immunological?

The latest P/E ratio of Bharat Immunological as of 21-Nov-2024 16:59 is 0.00.

What is the P/B ratio of Bharat Immunological?

The latest P/B ratio of Bharat Immunological as of 21-Nov-2024 16:59 is 0.00.

What is the 52-week high and low of Bharat Immunological?

The 52-week high of Bharat Immunological is ₹43.89 and the 52-week low is ₹22.25.

What is the TTM revenue of Bharat Immunological?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Bharat Immunological is ₹44.61 ( Cr.) .

About Bharat Immunologicals & Biologicals Corporation Ltd

Bharat Immunologicals and Biologicals Corporation Limited (BIBCOL) is a Central Public Sector Unit, under the Department of Biotechnology, Ministry of Science & Technology, Government of India. BIBCOL was established as a Public Sector Unit in 1989, with the aim to achieve self sufficiency for the nation with respect to production and supply of high quality polio vaccine, a dream project of the Former Prime Minister Late Rajiv Gandhi.

BIBCOLâ€™s principal mission is to save the lives of millions of children from avoidable disability, through polio vaccination. Since its inception, it has contributed significantly to the eradication of Poliomyelitis in the country through the National Immunization Program. BIBCOL is the pioneer in the field of polio vaccines, capturing 60% of total market share in India. The company has achieved a turnover of Rs.30.53 crores during the fiscal year 2005-2006 and earned a net profit of Rs.88.08 Lakhs. Based on the performance of the company and its world class WHO-cGMP certified infrastructure, highly skilled manpower and constant support from DBT, Government of India, BIBCOL is one among the top 20 Biotech companies in India, as revealed by recent market surveys.

Business area of the company:

The Company's principal activity is to manufacture and supply of oral polio vaccine. It supplies oral polio vaccine to Government of India. Its plant is located in Bulandshahr, Uttar Pradesh.

The live oral polio vaccine (OPV) is a trivalent vaccine containing suspensions of type 1,2 and 3 attenuated poliomyelitis viruses (Sabin strains) prepared in primary moneky kidney cell culture. Each dose contains Poliovirus type 1 = 106.0Poliovirus type 2 = 105.0Poliovirus type 3 = 105.8The vaccine contains stabilizers and traces of antibiotics.Doses: 0.1 ml (two drops)Packing Size: 3 ml vial contains 20 doses of OPVStorage: Vaccine is potent if stored at -20oC for 2 years

The trivalent OPV manufactured by BIBCOL is of excellent quality and complies with the GMP requirements of Shedule M of Drugs & Cosmetics Act of Government of India.

Milestones:

1989 - BIBCOL was established by Department of Biotechnology, Ministry of Science & Technology, Govt.of India as a Central Public Sector Unit and incorporated under the Companyâ€™s Act 1956.
1989 - About 30 young scientists and technologists from the field of Microbiology, Immunology, Biotechnology, Biochemistry, Pharmaceutical Sciences and Biochemical Engineering were recruited by DBT and trained in the field of vaccine production and quality control in reputed institutes in India and a specialized training at the Institute of Poliomyelitis and Viral Encephalitis, Moscow, Russia
1994- BIBCOL went public and the shares of the company were listed in Delhi, Mumbai and Kanpur stock exchanges
1996 -The company started formulating OPV from bulk since January 1996
1999 - The company acquired WHO-GMP certification
2000- BIBCOL bagged an order from UNICEF as well as from Ministry of Health and Family Welfare, Govt.of India for a total of 170 million doses
2001 - The company bagged another larger order of 270 million doses from UNICEF as well as from the Ministry of Health & Family Welfare, Govt.of India
2004- Due to the extensive restructuring with in the company, BIBCOL achieved a turn over of Rs.53.25 crore during the fiscal year 2004-2005 and has earned a net profit of 132.44 lacs for the first time against the loss pf Rs.3.14 crore during the previous fiscal year 2003-2004
2005 -For the first time, the company has signed a MoU with DBT for the fiscal year 2005-2006. The OPV plant at Chola, Bulandshahr has supplied about 1016 million doses of OPV to the National Immunization Program so far. During the year 2004-2005, 120 million doses were formulated and supplied to NIP, capturing nearly 60 percent of the total market share of polio vaccines in the country.
2006 - The company has secured a place among the Top 20 Biotech companies in the country through its commendable performance.